Volume 10, Number 5—May 2004
Research
Multidrug-resistant Tuberculosis in Central Asia
Helen Suzanne Cox*
, Juan Daniel Orozco*, Roy Male*, Sabine Ruesch-Gerdes†, Dennis Falzon*, Ian Small*, Darebay Doshetov‡, Yared Kebede§, and Mohammed Aziz¶
, Juan Daniel Orozco*, Roy Male*, Sabine Ruesch-Gerdes†, Dennis Falzon*, Ian Small*, Darebay Doshetov‡, Yared Kebede§, and Mohammed Aziz¶Table 3
First-line anti-tuberculosis drug resistance results, Dashoguz, Turkmenistana
| No. new cases (%) | No. retreatment cases(%) | Totalno. (%) | |
|---|---|---|---|
| Total tested | 105 | 98 | 203 |
| Any resistance | 32 (30.5) | 61 (62.2) | 93 (45.8) |
| Monoresistance | |||
| H only | 6 (5.7) | 8 (8.2) | 14 (6.9) |
| R only | 0 | 1 (1.0) | 1 (0.5) |
| E only | 0 | 0 | 0 |
| S only | 16 (15.2) | 13 (13.3) | 29 (14.3) |
| Z only | 0 | 0 | 0 |
| H and R resistance | |||
| MDR | 4 (3.8) | 18 (18.4) | 22 (10.8) |
| HR only | 0 | 0 | 0 |
| HRE only | 0 | 0 | 0 |
| HRS only | 3 (2.9) | 7 (7.1) | 10 (4.9) |
| HRZ only | 0 | 0 | 0 |
| HRES only | 1 | 6 (6.1) | 7 (3.4) |
| HREZ only | 0 | 0 | 0 |
| HRSZ only | 0 | 3 (3.1) | 3 (1.5) |
| HRESZ | 0 | 2 (2.0) | 2 (1.0) |
| H + other resistance | |||
| HE only | 0 | 1 (1.0) | 1 (0.5) |
| HS only | 5 (4.8) | 10 (10.2) | 15 (7.4) |
| HZ only | 0 | 1 (1.0) | 1 (0.5) |
| HES only | 1 (1.0) | 6 (6.1) | 7 (3.4) |
| HEZ only | 0 | 0 | 0 |
| HSZ only | 0 | 3 (3.1) | 3 |
| HESZ only | 0 | 0 | 0 |
| R + other resistance | |||
| RE only | 0 | 0 | 0 |
| RS only | 0 | 0 | 0 |
| RZ only | 0 | 0 | |
| RES only | 0 | 0 | 0 |
| RESZ only | 0 | 0 | 0 |
| Any drug resistance | |||
| Any H resistance | 16 (15.2) | 47 (48.0) | 63 |
| Any R resistance | 4 (3.8) | 19 (19.4) | 23 |
| Any E resistance | 2 (1.9) | 15 (15.3) | 17 |
| Any S resistance | 26 (24.8) | 50 (51.0) | 76 |
| Any Z resistance | 0 | 9 (9.2) | 9 |
aH, isoniazid; R, rifampin; E, ethambutol; S, streptomycin; Z, p, pyrizinamide.
